Moderna stock overview Moderna (MRNA) has drawn fresh attention after recent trading left the stock around $49.64, with returns mixed over the past week and month but well ahead year to date compared
It's important to consider your comfort with risk before diving in.
Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other busine
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.
Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.
In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of
View interactive chart, options flow, and AI analysis for MRNA on Zorveq Finance.
Open MRNA Chart & Analysis →